Restricted stock

NeuroOne Medical Technologies Corporation Announces Reverse Stock Split as Part of Uplisting Strategy to Major Exchange

Retrieved on: 
수요일, 3월 31, 2021
Financial markets, Corporate finance, Stock market, Financial economics, Finance, Equity securities, Options, Fundamental analysis, Reverse stock split, Warrant, Restricted stock, Stock

Dave Rosa, CEO of NeuroOne Medical Technologies Corporation says, "As part of our corporate strategy to uplist to a major exchange, we are excited to take the next step in this process.

Key Points: 
  • Dave Rosa, CEO of NeuroOne Medical Technologies Corporation says, "As part of our corporate strategy to uplist to a major exchange, we are excited to take the next step in this process.
  • We look forward to updating the market on our future progress as we move forward with a major national exchange."
  • The reverse stock split will reduce the number of shares of common stock issuable upon the exercise or vesting of its outstanding stock options, restricted stock units and warrants in proportion to the ratio of the reverse stock split and causes a proportionate increase in the exercise prices of such stock options and warrants.
  • The new CUSIP number for the common stock following the reverse split is 64130M 209.

Synchronoss Technologies, Inc. Reports Inducement Grants to Employees Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
목요일, 3월 25, 2021
Corporate finance, Stock market, Finance, Financial economics, Money, Employee stock ownership, Fundamental analysis, Restricted stock, Executive compensation, Stock

Each of these grants was an inducement award that was approved by the Compensation Committee of Synchronoss Board of Directors, and granted as an inducement equity award under the Company's 2017 New Hire Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • Each of these grants was an inducement award that was approved by the Compensation Committee of Synchronoss Board of Directors, and granted as an inducement equity award under the Company's 2017 New Hire Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Synchronoss granted the six newly hired employees an aggregate of 6,600 time-based restricted stock awards.
  • In addition, the employees received an aggregate of 2,200 time-based stock option awards.
  • Synchronoss secure, scalable and groundbreaking new technologies, trusted partnerships and talented people change the way TMT customers grow their business.

Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
금요일, 3월 19, 2021
Health, Pharmaceutical, Corporate finance, Stock market, Finance, Financial economics, Money, Employee stock ownership, Fundamental analysis, Restricted stock, Vesting, Executive compensation, Stock, Option

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted inducement stock options, inducement performance restricted stock units ("PRSUs"), and inducement restricted stock units ("RSUs") to new employees.

Key Points: 
  • Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted inducement stock options, inducement performance restricted stock units ("PRSUs"), and inducement restricted stock units ("RSUs") to new employees.
  • The inducement stock options, PRSUs, and RSUs each have a grant date and vesting commencement date (if applicable) of March 15, 2021, and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4).
  • ARENA Pharmaceuticals is a team with a singular purpose deliver our important medicines to patients.
  • Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Angion Announces Partial Waiver of Certain Lock-up Restrictions

Retrieved on: 
금요일, 3월 19, 2021
Financial markets, Stock market, Finance, Financial economics, Corporate finance, Equity securities, Restricted stock, Securities Act, Share, Security, Stock, Stifel

UNIONDALE, N.Y., March 19, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announcedCowen and Company, LLC and Stifel, Nicolaus & Company, Incorporated, the lead book-running managers in Angions recent public sale of 5,750,000 shares of common stock, have agreed to a partial wavier of a lock-up restriction with respect to approximately 100,267 shares of Angions common stock held by certain employees or officers of the company.

Key Points: 
  • UNIONDALE, N.Y., March 19, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announcedCowen and Company, LLC and Stifel, Nicolaus & Company, Incorporated, the lead book-running managers in Angions recent public sale of 5,750,000 shares of common stock, have agreed to a partial wavier of a lock-up restriction with respect to approximately 100,267 shares of Angions common stock held by certain employees or officers of the company.
  • The shares will be sold solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock or Restricted Stock Unit awards held by such employees pursuant to Angions employee equity incentive plans.
  • The waiver will take effect on March 23, 2021, and the shares may be sold on or after such date.
  • This press release is not an offer for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited and such securities may not be offered or sold in the United States absent registration or exemption from registration under the United States Securities Act of 1933, as amended.

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
금요일, 3월 5, 2021
Financial markets, Finance, Financial economics, Corporate finance, Stock market, Employee stock ownership, Fundamental analysis, Restricted stock, Flexion Therapeutics, Executive compensation, Stock, NASDAQ

BURLINGTON, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to four new employees consisting of 14,565 restricted stock units.

Key Points: 
  • BURLINGTON, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to four new employees consisting of 14,565 restricted stock units.
  • The Compensation Committee of the Board of Directors approved the grants with an effective date of March 1, 2021.
  • The restricted stock units were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The restricted stock units are subject to the terms and conditions of the Company's 2013 Equity Incentive Plan and a restricted stock unit agreement covering the grant.

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
금요일, 3월 5, 2021
Financial markets, Finance, Corporate finance, Financial economics, Stock market, Options, Equity securities, Fundamental analysis, Restricted stock, Stock, Exercise, NASDAQ

The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employees received options to purchase 33,650 shares of Apellis common stock and 825 restricted stock units (RSUs).
  • The options have an exercise price of $47.68, which is equal to the closing price of Apellis common stock on March 1, 2021, the grant date of the options.
  • Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies.

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
금요일, 3월 5, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Corporate finance, Employee stock ownership, Fundamental analysis, Restricted stock, Stock market, Labour law, Vesting, Urology, RSU, Finance, Law, Private law

UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced the grants of inducement restricted stock units (RSUs) to nine new employees in connection with their employment with UroGen.

Key Points: 
  • UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced the grants of inducement restricted stock units (RSUs) to nine new employees in connection with their employment with UroGen.
  • Up to 38,500 shares of UroGens common stock are issuable upon the vesting and settlement of the RSUs.
  • The RSUs are subject to the terms and conditions of UroGens 2019 Inducement Plan and RSU grant notice and agreement thereunder.
  • The RSU grants were granted as an inducement material to each employee entering into employment with UroGen in accordance with Nasdaq listing Rule 5635(c)(4).

Dycom Announces Authorization of a New $150 Million Stock Repurchase Program

Retrieved on: 
수요일, 3월 3, 2021
Corporate finance, Financial markets, Financial economics, Finance, Stock market, Equity securities, Fundamental analysis, Labour law, Vesting, Restricted stock, Stock, Common stock

PALM BEACH GARDENS, Fla., March 3, 2021 /PRNewswire/ -- Dycom Industries, Inc. (NYSE: DY) today announced that its Board of Directors has authorized a new $150 million program to repurchase shares of Dycom's outstanding common stock.

Key Points: 
  • PALM BEACH GARDENS, Fla., March 3, 2021 /PRNewswire/ -- Dycom Industries, Inc. (NYSE: DY) today announced that its Board of Directors has authorized a new $150 million program to repurchase shares of Dycom's outstanding common stock.
  • The repurchase program does not obligate Dycom to acquire any particular amount of common stock, and may be suspended or discontinued at any time.
  • As of March 2, 2021, the Company had 30,615,908 shares of common stock outstanding, excluding the dilutive effect of stock options and unvested restricted stock.
  • These services include program management; planning; engineering and design; aerial, underground, and wireless construction; maintenance; and fulfillment services for telecommunications providers.

Pacific Biosciences Grants Equity Incentive Award to New Employee

Retrieved on: 
화요일, 3월 2, 2021
Financial markets, Finance, Corporate finance, Financial economics, Stock market, Pacific Biosciences, Restricted stock, Stock, NASDAQ

MENLO PARK, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (Pacific Biosciences or the Company), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Companys Board of Directors granted non-qualified stock options covering an aggregate of 80,000 shares of Pacific Biosciences common stock and restricted stock units (RSUs) covering 40,000 shares of Pacific Biosciences common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the 2020 Inducement Plan) effective on February 25, 2021.

Key Points: 
  • MENLO PARK, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (Pacific Biosciences or the Company), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Companys Board of Directors granted non-qualified stock options covering an aggregate of 80,000 shares of Pacific Biosciences common stock and restricted stock units (RSUs) covering 40,000 shares of Pacific Biosciences common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the 2020 Inducement Plan) effective on February 25, 2021.
  • The options have an exercise price of $31.18 per share, which is equal to the closing price of Pacific Biosciences common stock on February 25, 2021 (the Effective Date).
  • The option grant and the award of restricted stock units are subject to the terms and conditions of the 2020 Inducement Plan and the award agreements entered into with the non-executive officer employee.
  • Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
토요일, 2월 27, 2021
Financial markets, Finance, Corporate finance, Stock market, Financial economics, Restricted stock, Stock, Option, NASDAQ

The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employees received, in the aggregate, options to purchase 1,820 shares of Sarepta's common stock, and in the aggregate 680 restricted stock units (RSUs).
  • The options have an exercise price of $87.06 per share, which is equal to the closing price of Sarepta's common stock on Feb. 26, 2021 (the Grant Date).
  • At Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease.